Live price
SUNPHARMA · Healthcare
₹1,840.00
−21.00 (−1.13%)
Day High
₹1,854.50
Day Low
₹1,834.00
52W High
₹2,046.90
52W Low
₹1,548.00
Volume today: 14.45 L
Key fundamentals
Market cap
₹3.8 L Cr
P/E ratio
35.0x
P/B ratio
4.8x
ROE
12.5%
Debt / Equity
—
Dividend yield
0.9%
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
BUYScore 69/100 · Medium confidence
Overall fundamentals and market signals are favourable. Consider for long-term portfolios with periodic review.
12M Price Target
₹2,024
Low ₹1,803 · High ₹2,300
Analyst-style Breakdown
Strong Buy
0
Buy
2
Hold
11
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum75/100
1M -5.3%, 1Y +15.4%
Earnings Trend80/100
Latest quarter revenue ₹15.2k Cr, profit ₹2.9k Cr
Valuation62/100
P/E 35.0x vs sector median ~35x
Financial Quality65/100
ROE 12.5%, ROCE 11.8%
Technical Position55/100
Trading between 52W low 1548 and high 2047
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹15.2k Cr | ₹2.9k Cr | ₹12.10 | +18.5% | +34.6% |
| Mar 2026 | ₹14.6k Cr | ₹2.7k Cr | ₹11.30 | — | — |
| Dec 2025 | ₹15.5k Cr | ₹3.4k Cr | ₹14.00 | — | — |
| Jun 2025 | ₹13.8k Cr | ₹2.3k Cr | ₹9.50 | — | — |
| Mar 2025 | ₹12.8k Cr | ₹2.1k Cr | ₹9.00 | — | — |
Reference Ratios
Market Capⓘ
₹3.8 L Cr
P/E Ratioⓘ
35.0x
P/B Ratioⓘ
4.8x
ROEⓘ
12.5%
ROCEⓘ
11.8%
Div Yieldⓘ
0.9%
Company Overview
Sun Pharma manufactures and sells generic drugs, specialty medicines, and branded formulations across India, US, and emerging markets.
Strengths
- + Strong US generic and specialty pipeline
- + India chronic therapy market leadership
- + Improving margin profile
- + Debt reduction and cash generation
Risks
- − US FDA inspection and compliance risk
- − Price erosion in US generics
- − Currency impact on US revenue
- − Patent cliff on specialty products
Latest News
No recent news articles for Sun Pharmaceutical yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Sun Pharmaceutical is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).